What is your GLP-1 actually costing you?
Enter your medication, your pharmacy price and where you started. You get your monthly and annual spend, what each pound has cost so far, what carrying on to target would cost, and a plain checklist for stopping well if that is where you are heading.
Your numbers
Prices are pre-filled with the manufacturer self-pay price for that dose (LillyDirect and NovoCare, September 2026; Foundayo October 2026). Change it to what you pay, especially if you use insurance, a coupon or a telehealth program.
What it costs
If you carry on
If this price and supply pattern continue, this is the estimated spending over your planning period. It does not predict your weight, how long treatment will be needed, or whether your prescription, price or coverage will change.
If you stop
This planner is independent of any pharmacy or manufacturer, so it can set out the other side of the decision plainly: the medication spending that would no longer apply, what the research does and does not say about regain, and a checklist to work through with your prescriber so that stopping is planned rather than abrupt.
Weight regain is common after weight-management medication is stopped, but its timing and extent vary. In the BMJ systematic review of 37 studies and 9,341 adults (West et al., 7 January 2026), average regain across all medicines was about 0.4 kg a month, and about 0.8 kg (1.8 lb) a month in the semaglutide and tirzepatide studies, over an average follow-up of 32 weeks. Research averages cannot predict your experience or establish that a checklist prevents regain. Discuss follow-up, nutrition, activity and any treatment changes with your prescriber.
Before your last dose
- Tell your prescriber you intend to stop and ask how they recommend doing it. Some step down, some stop outright. That decision is theirs and yours, not this page's.
- Ask what regain would prompt them to see you again, and write the number down. A threshold agreed in advance is easier to act on than a feeling.
- Record your last-dose date, your weight, your waist measurement and, if you have them, your recent blood results. This is your baseline for the next twelve weeks.
- Write down the three meals you eat most weeks on the medication. Those are your maintenance defaults, not something to redesign later.
- Decide now where the freed-up money goes each month, and keep one month's worth aside as a restart buffer so a return is a decision, not a scramble.
Weeks 1 to 4
- Keep the meal structure you already have: same times, protein-first plate, the portions you are used to. Review meals as appetite and nutritional needs change, and ask for individual support if you struggle to eat enough, feel unwell or find eating distressing.
- Expect hunger and food thoughts to come back. That is the medication leaving, not a failure. Have your planned snacks in the house before it happens.
- Weigh once a week, same day, same conditions. Daily weighing in this window produces noise and anxiety in equal measure.
- Keep water and fibre where they were. Both did quiet work while the medication was in the picture.
- Note any digestive changes. Most settle; anything that worries you is a call to your prescriber or pharmacist, not a forum.
Weeks 5 to 12
- Add one movement habit you can keep on a bad week. Resistance work twice a week protects the muscle you kept; a daily walk protects the routine.
- Sleep and alcohol both move appetite more than most people expect. If weight is creeping, look there before looking at food.
- Compare your week-12 weight with your baseline and with the threshold you agreed. If you have crossed it, book the appointment you already planned.
- Decide what maintenance looks like for the next year, in writing: the meals, the weigh-in day, the movement, the number that triggers a conversation.
How the planner works
How much does Zepbound cost per year without insurance?
Through Lilly's self-pay program, Zepbound costs US$299 per 28-day supply at 2.5 mg, US$399 at 5 mg and US$449 from 7.5 mg upward if you refill within the program's window, which is about US$3,887 to US$5,837 over 52 weeks. Lilly defines a supply as 28 days, one KwikPen or four single-dose vials, so 52 weeks is thirteen fills, not twelve. Miss the 45-day refill window on the higher doses and the price steps up to $499 to $699. Starting doses are short-term steps, not an annual treatment quote. Mounjaro is the same drug, tirzepatide, under the diabetes label, and is priced separately; the planner does not prefill Zepbound's offer as a Mounjaro price.
| Zepbound dose | Price per 28-day supply | Per 52 weeks (13 supplies) |
|---|---|---|
| 2.5 mg (starter) · short-term starting dose | US$299 | US$3,887 |
| 5 mg | US$399 | US$5,187 |
| 7.5 mg | US$449 | US$5,837 |
| 10 mg | US$449 | US$5,837 |
| 12.5 mg | US$449 | US$5,837 |
| 15 mg | US$449 | US$5,837 |
How much does Wegovy cost per year without insurance?
NovoCare's self-pay price for Wegovy is US$349 per box of four single-dose pens, a 28-day supply, at every dose from 1 mg to 2.4 mg, or about US$4,537 over 52 weeks on thirteen boxes. The US$199 starter price applies to the first two eligible fills only, under offer terms running to 31 December 2026, so a starter-dose year in the table is shown as two fills at $199 and eleven at $349 (about $4,237), marked with an asterisk; it is a conditional scenario, not a price guarantee. The 7.2 mg high-dose pen is $399. Telehealth subscriptions bundle the same pen with a consultation and typically run $370 to $450 a month; a retail pharmacy without a savings card can be close to $1,000.
| Wegovy pen dose | Price per 28-day supply | Per 52 weeks (13 supplies) |
|---|---|---|
| 0.25 mg (starter) · short-term starting dose | US$199 | US$4,237 * |
| 0.5 mg | US$199 | US$4,237 * |
| 1 mg | US$349 | US$4,537 |
| 1.7 mg | US$349 | US$4,537 |
| 2.4 mg | US$349 | US$4,537 |
How much does the Wegovy pill cost per month?
The Wegovy pill, once-daily oral semaglutide, launched in the US in January 2026. NovoCare's self-pay price is US$149 per 30-tablet bottle at the 1.5 mg starting dose, US$199 at 4 mg and US$299 at 9 mg and at the 25 mg maintenance dose (9 mg is an escalation step in the US label). Twelve bottles cover 360 days, not a full year; the table shows a 365-day equivalent, about US$3,638 at maintenance, while thirteen whole bottles would cost US$3,887 and provide 390 tablets. The starter price gets the headlines; the maintenance price is the one to plan around. Whether a tablet or an injection suits you is a question for your prescriber.
| Wegovy pill dose | Price per 30-tablet pack | Per 365 days (12 packs cover 360) |
|---|---|---|
| 1.5 mg daily (starter) · short-term starting dose | US$149 | US$1,813 |
| 4 mg daily (escalation) | US$199 | US$2,421 |
| 9 mg daily (escalation) | US$299 | US$3,638 |
| 25 mg daily (maintenance) | US$299 | US$3,638 |
How much does Foundayo cost without insurance?
Foundayo is orforglipron, a once-daily GLP-1 tablet from Lilly, approved by the FDA on 1 April 2026 and available in the US from 9 April 2026 in six strengths, from 0.8 mg to 17.2 mg. Through Lilly's self-pay program it costs US$149 per 30-day supply at the 0.8 mg starting dose and US$299 at 9 mg. At 14.5 mg and 17.2 mg it is US$299 if you refill within 45 days, otherwise US$349. Until 31 December 2026, 2.5 mg is temporarily US$149 (normally US$199) and 5.5 mg US$199 (normally US$299); the table counts three fills at the temporary price and the rest at the regular price, marked with an asterisk, as a conditional scenario rather than a price guarantee. Twelve 30-day supplies cover 360 days, so the table shows a 365-day equivalent: about US$3,638 a year at the higher doses. Foundayo and the Wegovy pill are different medicines with different dose steps, so the prices are not a like-for-like comparison. Whether a tablet or an injection suits you is a question for your prescriber.
| Foundayo dose | Price per 30-day supply | Per 365 days (12 supplies cover 360) |
|---|---|---|
| 0.8 mg daily (starter) · short-term starting dose | US$149 | US$1,813 |
| 2.5 mg daily | US$149 | US$2,271 * |
| 5.5 mg daily | US$199 | US$3,338 * |
| 9 mg daily | US$299 | US$3,638 |
| 14.5 mg daily | US$299 | US$3,638 |
| 17.2 mg daily (highest dose) | US$299 | US$3,638 |
Manufacturer self-pay list prices checked on 12 September 2026: zepbound.lilly.com/coverage-savings for Zepbound (28-day supply as a KwikPen or four single-dose vials; the $449 tier for 7.5 mg and above requires refilling within 45 days, otherwise $499 to $699) and novocare.com for Wegovy (box of four single-dose pens, 28 days; the $199 starter price covers the first two eligible fills only, offer terms to 31 December 2026; 30-tablet bottles for the pill). Foundayo prices were checked on 8 October 2026 at foundayo.lilly.com/coverage-savings (30-day supply; the temporary 2.5 mg and 5.5 mg prices and the savings card run to 31 December 2026; the $299 price on 14.5 mg and 17.2 mg requires refilling within 45 days, otherwise $349; Lilly may change these terms). Rows marked * are conditional introductory scenarios. Telehealth programs and retail pharmacies commonly charge more; insurance copays are usually far less. These tables are US reference prices; in other currencies the planner works from the price you type in. Refreshed quarterly.
How is cost per pound lost calculated?
Spend per pound lost is your total spend so far divided by the weight you have lost so far, in whichever unit you chose. It is a retrospective ratio, not a measure of value for money or a way to choose a treatment, and it only appears when your weight now is below your starting weight. If you leave the spend field blank, the planner estimates it as months on treatment multiplied by your current monthly cost. Your actual total may differ, which is why you can type it in.
How is the "if you carry on" figure worked out?
The planner takes your monthly cost at today's price and multiplies it by the planning period you choose: three, six or twelve months. For 28-day supplies the year is counted as thirteen supplies, which is 52 weeks or 364 days; for 30-tablet packs the yearly figure is a 365-day equivalent, and twelve packs cover 360 days. Where a starter price is introductory, the first eligible fills are counted at that price and the rest at the repeat price. It is a spending scenario at unchanged prices. It does not predict your weight, how long treatment will be needed, or whether your prescription, price or coverage will change.
What happens when you stop taking a GLP-1 medication?
Weight regain is common after weight-management medication is stopped, but its timing and extent vary from person to person. The BMJ systematic review published on 7 January 2026 (37 studies, 9,341 adults, average follow-up 32 weeks) found average regain of about 0.4 kg a month across all the medicines studied and about 0.8 kg (1.8 lb) a month in the semaglutide and tirzepatide studies, with modelled returns towards baseline over roughly one and a half to two years. Those are population averages; they cannot predict your experience or show that any checklist prevents regain. How to stop, whether to step down, and when to restart are decisions for you and your prescriber.
Who made this, and why is it free?
The planner is published by The Reset Edit Ltd (company 16430780, England and Wales) as part of GLP Reset™, an independent set of companion guides for people using or coming off GLP-1 medication, wherever they live. This edition is priced for the US; the other edition is linked at the top of the planner. We do not sell or prescribe medication, we take no referral fees from pharmacies, manufacturers or telehealth companies, and the planner does not require an email address. We make our money from the paid guides, which is why the free tool can be honest about stopping.
Not medical advice. This planner provides cost arithmetic and organisational support only. It does not recommend starting, stopping, tapering or changing the dose of any medication. Decisions about your treatment belong with your prescriber, pharmacist or doctor. If you experience symptoms that concern you, contact them.
Prices: see the tables above, September 2026 (Foundayo October 2026). Regain evidence: West S. et al., The BMJ, 7 January 2026 (Nuffield Department of Primary Care Health Sciences, University of Oxford). Last reviewed 8 October 2026.